Locations:
Search IconSearch

Chronic Pelvic Pain: Trial Examines Novel Intravaginal Electrical Stimulation Therapy

INSPIRE trial currently enrolling patients

16-obg-2071-inspired-650×450

By M. Jean Uy-Kroh, MD, and Elim Shih, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Chronic pelvic pain is a complex diagnosis that encompasses multiple conditions and organ systems. Its treatment is also challenging due to an incomplete understanding of pain processing.

Evidence confirms opioids worsen chronic pelvic pain by lowering pain thresholds and increasing pain sensitiv­ity. Nonpharmacological therapies are the treatment of choice. Physicians should counsel patients on the thera­peutic benefit of restorative sleep and exercise. One novel therapy using intra­vaginal electrical stimulation is currently under investigation at the Women’s Health Institute.

We are actively enrolling subjects in the INSPIRE (INtravaginal Stimulation for Pelvic Pain Improvement and Relief) trial, which is a randomized, controlled trial utilizing a nonimplanted, intravagi­nal electrical stimulation device within the comfort and privacy of the patient’s home.

Study design

The INSPIRE trial is a 12-week research study. We seek women diagnosed with chronic pelvic pain lasting longer than six months. Subjects are randomized into one of two study groups. One study group will use an active device and the other will use a sham device.

The trial requires four visits to Cleveland Clinic’s main campus. After enrollment, subjects must commit to perform home sessions using the device six times per week, 12 minutes per session, for a total of 12 weeks.

If the trial proves the active device sig­nificantly reduces pain, then the active device will be provided to all women in the study at no cost.

Being proactive matters

At Cleveland Clinic, we encourage women to take a more active role in the treatment of their chronic pelvic pain. If proven effective through ongoing research, a novel domiciliary device may be an alternative or adjunct therapy in chronic pelvic pain.

Advertisement

Dr. Uy-Kroh, Director of the Chronic Pelvic Pain Program, can be reached at 216.444.0551 or uykrohm@ccf.org. Dr. Shih is a former fellow in the Women’s Health Institute.

Advertisement

Related Articles

woman with milk and lettuce
Neighborhood Factors Affect Early Pregnancy Metabolic Health

Deprivation is linked to impaired glucose intolerance and racial disparities

23-WHI-4386458 – OGI – CQD – topical treatment for VIN
Trial Shows Promise for Topical Treatment for VIN

Artesunate ointment is safe well and tolerated patients with vulvar intraepithelial neoplasia

contraception
Update on Current Contraceptive Options

A case-based discussion of efficacy, eligibility and use

OB/GYN Residents Wellness
Wellness Efforts Are Needed by OB-GYN Residents, But One Solution Does Not Fit All

Workshop curriculum was valued by some, while others would have preferred time for themselves

Cecile Ferrando MD
Pain in Transgender Men Undergoing Hysterectomy

Study finds lower incidence of endometriosis than in cisgender patients

18-OBG-1364-DesaiAccessBlastocyst-650×450
Uninterrupted Culture in Time-Lapse Incubator Supports Human Embryonic Development

Large randomized study compares embryo growth kinetics and live birth rates between culture media

20-WHI-1938960 CQD WHI – Outcomes of Vaginoplasty Surgery – Ferrando_CQD Hero_650x450
Gender-Affirming Vaginoplasty: Reducing Complications

Surgeon experience is key to reducing adverse events

20-WHI-1878668-CQD-Predicting-Early-Pregnancy-Loss_Detti_CQD_650x450_A
Predicting Early Pregnancy Loss: Insights from Early, Serial Ultrasounds in Pregnancy

Introducing Laura Detti, MD, newly appointed Chair of the Department of Subspecialty Care for Women’s Health

Ad